|1.||Xia, Qiang: 6 articles (08/2010 - 01/2005)|
|2.||Mao, Hong-Jiao: 4 articles (08/2010 - 01/2005)|
|3.||Chen, Bao-Ping: 4 articles (08/2010 - 01/2005)|
|4.||Li, Juan: 3 articles (03/2013 - 12/2010)|
|5.||Fan, Fang-Yan: 3 articles (02/2006 - 01/2005)|
|6.||Yalcin, Ipek: 2 articles (02/2015 - 11/2008)|
|7.||Barrot, Michel: 2 articles (02/2015 - 11/2008)|
|8.||Fan, Rong: 2 articles (03/2013 - 12/2010)|
|9.||Guo, Hai-Tao: 2 articles (12/2010 - 05/2009)|
|10.||Wang, Yue-Min: 2 articles (12/2010 - 05/2009)|
03/01/2007 - "Nor-BNI decreased the threshold for PTZ-evoked seizures and increased seizure incidence during the initial induction of kindling relative to controls. "
08/01/2006 - "Pretreatment with nor-binaltorphimine significantly increased handling-induced convulsion (HIC) severity in withdrawing WSR mice, with no observable effects in withdrawing WSP mice. "
01/01/1989 - "At the doses and injection routes used, nor-BNI itself had no apparent effect on overt behavior or MES-induced convulsions. "
01/01/1989 - "Selective kappa antagonist properties of nor-binaltorphimine in the rat MES seizure model."
02/09/1993 - "Norbinaltorphimine protection against N-methyl-D-aspartic acid-induced convulsions and mortality."
|2.||Wounds and Injuries (Trauma)
01/01/1987 - "Given intrathecally, at doses that were ineffective systemically (0.1 mg/kg), nor-BNI also significantly improved neurological recovery after trauma. "
01/01/1987 - "Nor-BNI, at a dose of 10 mg/kg administered intravenously at 15 min following impact trauma to T-9, significantly improved neurological recovery, measured both in terms of Tarlov motor scores and ability to maintain position on an inclined plane. "
01/01/1987 - "Because of the proposed role of kappa-opiate receptors in mediating secondary damage after spinal trauma, the effect of nor-BNI was studied in a well-characterized model of traumatic spinal cord injury in rats. "
04/25/2011 - "On day 21, after complete recovery of mechanical thresholds and healing of the wound, one of the following drugs was administered subcutaneously: (-)-naloxone (1mg/kg), (+)-naloxone (1mg/kg), naloxone-methiodide (3mg/kg), or nor-binaltorphimine (5mg/kg). "
01/01/1990 - "To evaluate this hypothesis further, effects of intrathecally administered dynorphin (Dyn) A-(1-17), dynorphin antiserum, or the kappa-selective opiate antagonist nor-binaltorphimine (nor-BNI) were studied in rats subjected to standardized impact trauma to the thoracic spinal cord. "
11/01/2005 - "Meanwhile, intravenous administration of delta and kappa opioid receptor antagonists ICI174,864 and Nor-BNI also significantly increased the mean arterial blood pressure, improved the hemodynamic parameters, and prolonged the survival rate of traumatic shock rats. "
11/01/2005 - "Intracerebral ventricular administration of ICI174,864 and Nor-BNI significantly antagonized the decreased cardiovascular function after traumatic shock and increased the survival rate of traumatic shock rats, but mu opioid receptor antagonist beta-funaltrexamine did not. "
11/01/2005 - "Traumatic shock was used in pentobarbital-anesthetized Wistar rats by right femur fracture plus hemorrhage (fixed hemorrhage at a rate of 20 mL/kg in experiment 1 or hemorrhage to 40 mmHg mean arterial blood pressure for 60 min in experiments 2 and 3), and the changes of myocardial and brain opioid receptors after traumatic shock, the antagonizing effects of mu, delta, and kappa opioid receptor antagonists on the cardiovascular depression of traumatic shock and the antishock effects of delta and kappa opioid receptor antagonists ICI174,864 and Nor-binaltorphimine (Nor-BNI) were observed. "
03/01/1994 - "Studies were conducted in which pretreatment with nor-BNI (2, 10 and 20 micrograms i.t.) selectively blocked delta 9-THC-induced antinociception while not significantly affecting other commonly observed cannabinoid actions, which included hypothermia, hypoactivity and catalepsy. "
05/01/2005 - "The i.c.v. administration of nor-BNI, a kappa-opioid antagonist, did not affect the hypothermia produced by the systemic injection of ICI 204448. "
09/01/2002 - "U50,488H-induced hypothermia was antagonized by the kappa antagonist nor-binaltorphimine but not by acute treatment with the irreversible kappa antagonist DIPPA. "
12/01/1992 - "Dynorphin A1-17 (4.65 nM), a kappa-selective agonist, reduced both Vo2 and Q, resulting in hypothermia that was blocked by the kappa-selective antagonist nor-binaltorphimine (25 nM). "
06/20/1996 - "In addition, nor-binaltorphimine had no effect on diazepam-induced motor incoordination, hypothermia or anticonvulsant action, respectively. "
02/01/1994 - "Dorsal horn neurones showed a bidirectional change in response as carrageenan-induced inflammation developed, although the direction of this change did not correlate with the subsequent direction of effect of nor-BNI. "
12/01/2001 - "The morphine-induced increase in dopamine turnover in the limbic forebrain was suppressed under inflammation, and the suppression was abolished by the pretreatment with nor-BNI. "
01/01/2001 - "The morphine-induced increase in dopamine (DA) turnover in the limbic forebrain was suppressed under inflammation, and the suppression was abolished by the pretreatment with nor-BNI. "
01/01/1999 - "In the present study, to elucidate the mechanism of this attenuation, the effects of pretreatment with delta- and kappa-opioid receptor antagonists, naltrindole (NTI) and nor-binaltorphimine (nor-BNI), on the development of the morphine-induced place preference under inflammation were examined in rats. "
12/01/2001 - "Therefore, to elucidate the mechanism of this attenuation, the effects of pretreatment with kappa- and delta-opioid receptor antagonists, nor-binaltorphimine (nor-BNI) and naltrindole (NTI), on the development of the morphine-induced place preference under inflammation were examined. "
|1.||kappa Opioid Receptors (kappa Opioid Receptor)
|4.||Opioid Receptors (Opioid Receptor)
|6.||Morphine (MS Contin)
|10.||Deoxyglucose (2 Deoxy D glucose)